Translational Platforms to Model Pre-Diabetes, Diabetes, and Diabetic Complications
Presented by Dr. Judith Gorski, Global Director, Scientific Engagement, Crown Bioscience Inc.
A key challenge in preclinical studies of diabetes is the lack of translational platforms that can model the various aspects of disease progression and associated complications.
In this webinar, Dr. Gorski will present the development and utility of CrownBio's unique continuum of translational platforms that model various aspects of diabetes and metabolic syndrome, and how such platforms are used to predict the efficacy and safety of anti-diabetic therapies in humans.
This presentation highlights the development of the ZDSD rat model, one of the most translational rodent model of pre-diabetes, diabetes, and diabetic complications (such as diabetic nephropathy). It also features a discussion on a spontaneously dysmetabolic and diabetic non-human primate model, and how insulin resistance and type 2 diabetes in this model bear close similarity to obesity-mediated insulin resistance in humans and we share case studies on the utility of this model as a platform for therapeutics that ameliorate insulin resistance.
Watch This Webinar To Learn:
- The latest rodent and non-human primate translational models to study diabetes pathology
- Modeling pre-diabetes, diabetes progression, and associated complications (e.g. nephropathy) in these models
- Examples of how these models are used to assess efficacy and safety of anti-diabetes therapeutics
Watch The Webinar Now!
About The Presenter:
Dr. Judith Gorski is Global Director of Scientific Engagement at Crown Bioscience Inc., and is a pharmacologist with over 18 years of experience in drug discovery and development in a large pharmaceutical environment. She has extensive experience in basic research and targeted drug discovery in the disease areas of type 1 and 2 diabetes, dyslipidemia, atherosclerosis, obesity, and metabolic syndrome. Dr. Gorski has co-authored publications in Nature, Obesity, Obesity Research, Cell Metabolism, Journal of Lipid Metabolism.
Prior to joining CrownBio, Dr. Gorski's work at Merck focused on target identification/validation and small molecule and biologics identification/optimization with the aim of recommending lead candidates for clinical development. She is an expert at establishing and validating primary, secondary and tertiary in vivo models of dyslipidemia, obesity, metabolic syndrome, and type 1 and 2 diabetes.
Dr. Gorski received her Ph.D. in Neuroscience from University of Medicine and Dentistry, New Jersey.